Ozempic for PCOS and weight loss: what 9 months of TikTok updates miss

What did @newnursegrad actually say?

This nursing grad shared a nine-month Ozempic update, claiming she lost roughly 60-65 pounds, dropping from 188 to 123 pounds. She's being treated by an endocrinologist, plans to ask for a dietitian referral, and openly worried about what happens if she stops the medication. She also mentioned her muscles have atrophied, calling her current physique "pretend muscles" made of fat.

To her credit, she didn't make wild therapeutic claims. She didn't say Ozempic cured her PCOS or fixed her insulin resistance permanently. She described her own experience, flagged legitimate concerns about long-term use, and is actively seeking professional guidance. That's a more responsible framing than most GLP-1 content on TikTok.

Does the science back this up?

A 65-pound loss over nine months is on the high end of documented outcomes, but not implausible. Clinical trial data shows wide individual variation in response to semaglutide.

The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) reported average weight loss of about 14.9% of body weight over 68 weeks in adults without diabetes. Starting at 188 pounds, that would imply roughly 28 pounds on average. This creator claims about 35% of her starting body weight lost, which is well above average. That doesn't mean she's lying. Individual response varies considerably, and PCOS-related insulin resistance can mean some patients had further to fall metabolically before treatment. But it does mean her result is an outlier, not a benchmark viewers should expect for themselves.

Her concern about weight regain after stopping is well-supported. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who stopped semaglutide after 20 weeks regained about two-thirds of lost weight within a year. That fear is grounded in real data.

What did they get wrong (or right)?

The muscle loss observation is accurate and underappreciated. She's right that GLP-1-driven weight loss doesn't spare lean mass by default.

A 2023 analysis by Ida et al. in Diabetes, Obesity and Metabolism confirmed that semaglutide-induced weight loss includes a meaningful proportion of lean body mass, not just fat. Without resistance training and adequate protein intake, users can lose significant muscle alongside fat. Her instinct to "start building muscle" next is clinically sound advice, not just aesthetic preference.

Where she's imprecise: she uses "muscles are gone" loosely. Muscle atrophy from caloric restriction is real but also partially reversible with resistance training. Her framing is a bit alarmist but directionally correct.

She also calls her excess tissue "fat muscles," which isn't a clinical concept. Subcutaneous fat and skeletal muscle are distinct tissue types. Minor point, but worth clarifying for an audience of healthcare students following her account.

What should you actually know?

Three things matter here that the video glosses over.

• Her results are not average. Losing 35% of body weight in nine months is exceptional. Most semaglutide users lose 10-15% of body weight in clinical trials. If you're on Ozempic and losing slower, that's normal, not failure.
• Weight regain after stopping is a documented risk, not a personal weakness. The STEP 4 data is clear. Semaglutide appears to work partly by suppressing appetite signals that return when the drug stops. This is a physiological phenomenon, not a willpower issue.
• Muscle loss during GLP-1 treatment is a real clinical concern. Protein intake and resistance exercise aren't optional add-ons. Current clinical guidance, including recommendations from obesity medicine specialists, emphasizes both during active weight loss on GLP-1 agonists.

She's seeing an endocrinologist and pursuing a dietitian referral. That's the right model. Anyone using GLP-1 medications for PCOS or weight management should have the same level of professional oversight, not just a TikTok update schedule.